<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02628964</url>
  </required_header>
  <id_info>
    <org_study_id>14-01178</org_study_id>
    <nct_id>NCT02628964</nct_id>
  </id_info>
  <brief_title>Electronic Cigarettes (E-cigarettes) as a Harm Reduction Strategy</brief_title>
  <official_title>Assessing the Use of Electronic Cigarettes (E-cigarettes) as a Harm Reduction Strategy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the feasibility of using e-cigarettes as a method for
      harm reduction and the effects of providing e-cigarettes (or placebo e-cigarettes) on smoking
      outcomes. Participants will be randomized to receive either e-cigarettes with nicotine
      cartridges or e-cigarettes with placebo cartridges, and followed for 3 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot study will be a two-arm, randomized controlled trial. The investigator will
      randomize 40 participants into each intervention arm. Participants will be randomized to one
      of the two arms: e-cigarettes with nicotine cartridges or e-cigarettes with placebo
      cartridges (0mg). Participants and research assistants will be blind to the allocation of
      nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist
      emitted from the e-cigarettes with and without nicotine containing cartridges. Participants
      will be asked to track their nicotine use via text message. All participants will receive a
      20-30 minute behavioral counseling consultation with a trained tobacco counselor. Counselors
      will review each participant's smoking pattern and offer tailored behavioral and
      environmental change strategies including specific smoking reduction strategy options.
      Participants will be given a supply of e-cigarettes and followed for 3 weeks
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">March 26, 2018</completion_date>
  <primary_completion_date type="Actual">March 26, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the Number of Cigarettes Per Day (CPD)</measure>
    <time_frame>Baseline up to 3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Participants Who Achieve 50% Reduction in Number of Cigarettes Per Day at 3 Weeks.</measure>
    <time_frame>up to 3 weeks</time_frame>
    <description>Using the percent difference in number of cigarettes per day from baseline to 3-weeks, the proportion of participants who reduced their cigarette usage per day by 50% or greater</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants in Each Arm Who Reported Side Effects</measure>
    <time_frame>3 weeks</time_frame>
    <description>Percentage of participants who responded yes to a yes/no question about experiencing any side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Using Additional Tobacco Products and/or Marijuana</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Satisfaction Rating for the E-cigarettes</measure>
    <time_frame>3 weeks</time_frame>
    <description>Percent of participants who reported either &quot;Strongly Agree&quot; or &quot;Agree&quot; to liking using e-cigarettes at 3-weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Nicotine Urges/Cravings</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Withdrawal Symptoms</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>No data displayed because Outcome Measure has zero total participants analyzed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>4.5% e-cig</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>e-cigarettes with nicotine cartridges</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0 mg e-cig</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>e-cigarettes with placebo cartridges (0mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>e-cigarettes</intervention_name>
    <description>Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.</description>
    <arm_group_label>0 mg e-cig</arm_group_label>
    <arm_group_label>4.5% e-cig</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  21-35 years old

          -  daily smokers who smoke at least 10 cigarettes per day (CPD)

          -  interested in reducing CPDs

          -  able to provide consent

          -  Use a cell phone and are willing/able to receive and respond to daily text messages
             regarding their cigarette use and e-cigarette use on their cell phone

          -  Willing to use an e-cigarette for 3 weeks

        Exclusion Criteria:

          -  pregnant and/or breast feeding

          -  currently using smoking cessation medications (including other forms of Nicotine
             Replacement Therapy (NRT), buproprion, or varenicline)

          -  enrolled in a smoking cessation program or another cessation trial

          -  have used an e-cigarette in the past 14 days

          -  have used any other tobacco products (pipe, cigar, cigarillos, snuff, chewing tobacco,
             rolling tobacco, or hookah/shisha) in the past 30 days

          -  score ≥7 (men) or ≥5 (women) on the Alcohol Use Disorders Identification Test
             (AUDIT-C),

          -  score ≥ 5 on the Drug Abuse Screening Test-10 (DAST)

          -  report having a history of asthma, other airways diseases, or heart disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donna Shelley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 28, 2015</study_first_submitted>
  <study_first_submitted_qc>December 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2015</study_first_posted>
  <results_first_submitted>July 24, 2019</results_first_submitted>
  <results_first_submitted_qc>February 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 24, 2020</results_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>smoking</keyword>
  <keyword>cigarettes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 22, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT02628964/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>4.5% E-cig</title>
          <description>e-cigarettes with nicotine cartridges
e-cigarettes: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.</description>
        </group>
        <group group_id="P2">
          <title>0 mg E-cig</title>
          <description>e-cigarettes with placebo cartridges (0mg).
e-cigarettes: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>4.5% E-cig</title>
          <description>e-cigarettes with nicotine cartridges
e-cigarettes: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.</description>
        </group>
        <group group_id="B2">
          <title>0 mg E-cig</title>
          <description>e-cigarettes with placebo cartridges (0mg).
e-cigarettes: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="99"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Non-Hispanic African American/black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-Hispanic white</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other non-Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic of any race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in the Number of Cigarettes Per Day (CPD)</title>
        <time_frame>Baseline up to 3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4.5% E-cig</title>
            <description>e-cigarettes with nicotine cartridges
e-cigarettes: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.</description>
          </group>
          <group group_id="O2">
            <title>0 mg E-cig</title>
            <description>e-cigarettes with placebo cartridges (0mg).
e-cigarettes: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Number of Cigarettes Per Day (CPD)</title>
          <units>cigarettes per day (CPD)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="5.1"/>
                    <measurement group_id="O2" value="7.3" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Participants Who Achieve 50% Reduction in Number of Cigarettes Per Day at 3 Weeks.</title>
        <description>Using the percent difference in number of cigarettes per day from baseline to 3-weeks, the proportion of participants who reduced their cigarette usage per day by 50% or greater</description>
        <time_frame>up to 3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4.5% E-cig</title>
            <description>e-cigarettes with nicotine cartridges
e-cigarettes: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.</description>
          </group>
          <group group_id="O2">
            <title>0 mg E-cig</title>
            <description>e-cigarettes with placebo cartridges (0mg).
e-cigarettes: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants Who Achieve 50% Reduction in Number of Cigarettes Per Day at 3 Weeks.</title>
          <description>Using the percent difference in number of cigarettes per day from baseline to 3-weeks, the proportion of participants who reduced their cigarette usage per day by 50% or greater</description>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".7"/>
                    <measurement group_id="O2" value=".49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants in Each Arm Who Reported Side Effects</title>
        <description>Percentage of participants who responded yes to a yes/no question about experiencing any side effects</description>
        <time_frame>3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4.5% E-cig</title>
            <description>e-cigarettes with nicotine cartridges
e-cigarettes: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.</description>
          </group>
          <group group_id="O2">
            <title>0 mg E-cig</title>
            <description>e-cigarettes with placebo cartridges (0mg).
e-cigarettes: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants in Each Arm Who Reported Side Effects</title>
          <description>Percentage of participants who responded yes to a yes/no question about experiencing any side effects</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5"/>
                    <measurement group_id="O2" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Using Additional Tobacco Products and/or Marijuana</title>
        <time_frame>Up to 12 weeks</time_frame>
        <population>no data were collected for this Outcome Measure</population>
        <group_list>
          <group group_id="O1">
            <title>4.5% E-cig</title>
            <description>e-cigarettes with nicotine cartridges
e-cigarettes: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.</description>
          </group>
          <group group_id="O2">
            <title>0 mg E-cig</title>
            <description>e-cigarettes with placebo cartridges (0mg).
e-cigarettes: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Using Additional Tobacco Products and/or Marijuana</title>
          <population>no data were collected for this Outcome Measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Satisfaction Rating for the E-cigarettes</title>
        <description>Percent of participants who reported either &quot;Strongly Agree&quot; or &quot;Agree&quot; to liking using e-cigarettes at 3-weeks</description>
        <time_frame>3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4.5% E-cig</title>
            <description>e-cigarettes with nicotine cartridges
e-cigarettes: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.</description>
          </group>
          <group group_id="O2">
            <title>0 mg E-cig</title>
            <description>e-cigarettes with placebo cartridges (0mg).
e-cigarettes: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Satisfaction Rating for the E-cigarettes</title>
          <description>Percent of participants who reported either &quot;Strongly Agree&quot; or &quot;Agree&quot; to liking using e-cigarettes at 3-weeks</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="71.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Nicotine Urges/Cravings</title>
        <time_frame>Up to 12 weeks</time_frame>
        <population>no data were collected for this Outcome Measure</population>
        <group_list>
          <group group_id="O1">
            <title>4.5% E-cig</title>
            <description>e-cigarettes with nicotine cartridges
e-cigarettes: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.</description>
          </group>
          <group group_id="O2">
            <title>0 mg E-cig</title>
            <description>e-cigarettes with placebo cartridges (0mg).
e-cigarettes: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Nicotine Urges/Cravings</title>
          <population>no data were collected for this Outcome Measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Withdrawal Symptoms</title>
        <description>No data displayed because Outcome Measure has zero total participants analyzed.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>no data were collected for this Outcome Measure</population>
        <group_list>
          <group group_id="O1">
            <title>4.5% E-cig</title>
            <description>e-cigarettes with nicotine cartridges
e-cigarettes: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.</description>
          </group>
          <group group_id="O2">
            <title>0 mg E-cig</title>
            <description>e-cigarettes with placebo cartridges (0mg).
e-cigarettes: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Withdrawal Symptoms</title>
          <description>No data displayed because Outcome Measure has zero total participants analyzed.</description>
          <population>no data were collected for this Outcome Measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>4.5% E-cig</title>
          <description>e-cigarettes with nicotine cartridges
e-cigarettes: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.</description>
        </group>
        <group group_id="E2">
          <title>0 mg E-cig</title>
          <description>e-cigarettes with placebo cartridges (0mg).
e-cigarettes: Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Donna Shelley, MD MPH</name_or_title>
      <organization>NYU Langone Health</organization>
      <phone>917-494-4210</phone>
      <email>donna.shelley@nyulangone.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

